Meta-Analysis of NFKB1 -94 ATTG Ins/Del Polymorphism and Risk of Breast Cancer

(E-pub Ahead of Print)

Author(s): Jyothsna Kancharla, Vara Prasad I. Devi, Bhaskar VKS Lakkakula*, Bramhachari Pallaval Veera, Alam Afroz.

Journal Name: Current Drug Metabolism

Become EABM
Become Reviewer


Background: Breast cancer (BC) accounts for one of the most prevalent malignances the world. Inflammatory molecules modulate tumor microenvironment in BC that promotes tumor growth and metastasis. NF-κB (a transcription factor) that regulates multiple immune functions and acts as a crucial mediator of inflammatory responses.

Objective: The present study is aimed to quantitatively summarize the relation of NFKB1 -94 ATTG (I, insertion/D, deletion) variant and risk of BC.

Materials and Methods: Further, the meta-analysis includes three independent case-control investigations that focus on NFKB1 -94, ATTG I/D polymorphism, and BC patients. Web of Science, PubMed and Embase databases were used to retrieve relevant data. OR and 95% confidence interval of pooled studies were analyzed by using the MetaGenyo web tool.

Results: This study revealed high heterogeneity. In all three genetic comparison models, the NFKB1 -94 ATTG I/D variant is not related with the risk of BC. Further, no publication bias on the connection between NFKB1 -94 ATTG I/D variant and risk of BC.

Conclusion: To summarize, our meta-analysis demonstrates that the NFKB1 -94 ATTG I/D polymorphism is not a major risk factor for BC.

Keywords: Breast Cancer, Inflammation, NFKB1 -94, ATTG I/D polymorphism, meta-analysis, transcription factor

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389200221666200310113118
Price: $95

Article Metrics

PDF: 1